Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 1998

View Archived Issues

Genzyme Tissue Repair: Q2 1998 highlights

Inhale Therapeutic Systems: Q2 1998 highlights

SmithKline Beecham licenses rights to Immunex's G-CSF receptor for R&D purposes

Vertex solves 3D structure of JNK3, an enzyme implicated in epilepsy and stroke

Yoshitomi claims safe and effective new antipsychotic agents

First application of Medtronic's neurostimulator in two patients with Parkinson's disease

Immune Response evaluates rheumatoid arthritis vaccine in follow-up trial

LY-341495 proves to be a potent tool in the study of metabotropic glutamate receptor function

Octreotide pamoate as a treatment for advanced GI and pancreatic cancer shown to alter IGF system

Mitsui Chemical reports discovery of cell differentiation-inducing agents

Tanabe Seiyaku team identifies new candidates for asthma

Hoechst describes novel antibiotic feglymycin

New tocolytic agents in the pipeline at Kissei

Cell adhesion-inhibitory peptides under investigation at Hisamitsu

Mitsui Toatsu researches cell adhesion inhibitors for a range of potential indications

Compound, composition and method for treating cancer available for licensing from NIH

New clinical study evaluating INKP-100 now in progress

NIAID will collaborate with VaxGen on phase III AIDSVAX studies

Nabi files PLA, ELA for hepatitis B immune globulin

Amgen discontinues clinical testing of PEG-rHuMGDF for one of two indications

Canadian launch announced for Zyban sustained-release tablets

HemispheRx announces first regulatory filing for CFS/ME treatment agent

International team identifies selective P2X antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...